The diagnostic odyssey, clinical burden, and natural history of Barth syndrome: an analysis of patient registry data

Abstract

Aim: Barth syndrome (BTHS; OMIM 302060) is an ultra-rare, complex, multi-system X-linked disorder that arises from pathogenic mutations in the gene TAFAZZIN. BTHS is characterized by cardiomyopathy, skeletal myopathy, muscle weakness, and neutropenia. To better understand the natural history and lived experience of affected individuals, the Barth Syndrome Foundation maintains the patient-inputted Barth Syndrome Registry and Repository (BRR).

Methods: Available cross-sectional and longitudinal participant data (n = 115) were analyzed to illustrate the diagnostic odyssey, manifestations, and healthcare utilization across a broad range of affected individual age groups.

Results: Individuals who experienced cardiomyopathy or heart failure as the first manifestation had the shortest times to diagnosis compared to less appreciated manifestations (e.g., frequent infections, poor muscle tone, growth delay). The most frequently reported manifestations across all ages were due to cardiac disorders (80.7%), gastrointestinal (GI) disorders (68.7%), neutropenia or frequent infections (67.2%), and fatigue (60.9%), with 47.1% of participants scoring in the moderate-to-severe range of the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 8A survey. Participants saw, on average, 3.6 specialists in the previous year, with cardiologists (97.9%) and hematologists (58.2%) being the most commonly seen specialists.

Conclusion: The data suggest that cardiac disorders are the most common manifestations of BTHS, but also reveal a high frequency of feeding and GI-related issues that previous reports have not captured. Physician-targeted education on the lesser-known symptoms and population-based screening for BTHS may aid in timely diagnosis and improved clinical management.

Keywords

Barth syndrome / natural history / diagnostic odyssey / cardiomyopathy / neutropenia / gastrointestinal / fatigue

References

[1] Ferreira C,Thompson R. Barth Syndrome. Available from: https://www.ncbi.nlm.nih.gov/books/NBK247162/ [Last accessed on 13 Sep 2024].

[2] Gonzalez IL.Barth syndrome: TAZ gene mutations, mRNAs, and evolution.Am J Med Genet A2005;134:409-14

[3] Bione S,Maestrini E,Bolhuis PA.A novel X-linked gene, G4.5 is responsible for Barth syndrome.Nature Genetics1996;12:385-9

[4] Cosson L,Simard G.Barth syndrome in a female patient.Mol Genet Metab2012;106:115-120

[5] Avdjieva-Tzavella DM,Kathom HM.Barth syndrome in male and female siblings caused by a novel mutation in the TAZ gene.Genetic Counseling2016;27:495-501

[6] Xu Y,Ren M.The enzymatic function of tafazzin.J Biol Chem2006;281:39217-24

[7] Schlame M.The function of tafazzin, a mitochondrial phospholipid–lysophospholipid acyltransferase.J Mol Biol2020;432:5043-51 PMCID:PMC7483898

[8] Kagan VE,Mikulska-Ruminksa K.Anomalous peroxidase activity of cytochrome c is the primary pathogenic target in Barth syndrome.Nature Metabolism2023;5:2184-205 PMCID:PMC11213643

[9] Ji J.Cardiolipin function in the yeast S: cerevisiae and the lessons learned for Barth syndrome.J Inherit Metab Dis2022;45:60-71 PMCID:PMC8755574

[10] Paradies G,Ruggiero FM.Role of cardiolipin in mitochondrial function and dynamics in health and disease: molecular and pharmacological aspects.Cells2019;8:728 PMCID:PMC6678812

[11] Ren M,Schlame M.A critical appraisal of the tafazzin knockdown mouse model of Barth syndrome: what have we learned about pathogenesis and potential treatments?.Am J Physiol Heart Circ Physiol2019;317:H1183-H1193 PMCID:PMC6962617

[12] Vaz FM,Vervaart MAT.An improved functional assay in blood spot to diagnose Barth syndrome using the monolysocardiolipin/cardiolipin ratio.J Inherit Metab Dis2022;45:29-37 PMCID:PMC9291596

[13] Barth PG,Berden JA.An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes.J Neurol SCI1983;62:327-355

[14] Kelley RI,Clark BJ.X-linked dilated cardiomyopathy with neutropenia, growth retardation, and 3-methylglutaconic aciduria.J Pediatr-US1991;119:738-47

[15] Hornby B,Almuqbil M.Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.Orphanet J Rare Dis2022;17:1-9 PMCID:PMC9438322

[16] Roberts AE,Steward CG.The barth syndrome registry: distinguishing disease characteristics and growth data from a longitudinal study.Am J Med Genet A2012;158:2726-32

[17] Steward CG,Taylor CT.Neutropenia in Barth syndrome. characteristics, risks, and management.Curr Opin Hematol2019;26:6-15 PMCID:PMC6392059

[18] A report on the externally-led patient-focused drug development meeting. Available from: https://barthsyndrome.org/newsevents/pfddmeeting/voiceofthepatient.html. [Last accessed on 13 Sep 2024]

[19] Taylor C,Pierre G.Clinical presentation and natural history of Barth Syndrome: an overview.J Inherit Metab Dis2022;45:7-16

[20] Reynolds S.Successful management of Barth syndrome. a systematic review highlighting the importance of a flexible and multidisciplinary approach.J Multidiscip Health2015;8:345-58 PMCID:PMC4524586

[21] Lontok E,Bowen VM.Barth syndrome foundation. From humble beginnings to becoming an integral partner.J Inherit Metab Dis2022;45:3-6

[22] Barth syndrome registry and repository. Available from: https://barthsyndromeregistry.patientcrossroads.org. [Last accessed on 13 Sep 2024]

[23] Mazar I,Ollis S.Understanding the life experience of Barth syndrome from the perspective of adults. a qualitative one-on-one interview study.Orphanet J Rare Dis2019;14:1-8 PMCID:PMC6836365

[24] PROMIS Fatigue Scoring Manual. Available from: https://www.fda.gov/media/137977/download [Last accessed on 13 Sep 2024]

[25] Kang SL,Dudley D,Tsai-Goodman B.Clinical characteristics and outcomes of cardiomyopathy in Barth syndrome: the UK experience.Pediatric Cardiology2016;37:167-17

[26] Takeda A,Yamada M.Eponym: Barth syndrome.Eur J Pediatr2011;170:1365-7

[27] Wilson JMG. Principles and practice of screening for disease. Available from: https://apps.who.int/iris/handle/10665/37650 [Last accessed on 13 Sep 2024]

[28] Ross LF.A historical and current review of newborn screening for neuromuscular disorders from around the world: lessons for the United States.Pediatric Neurology2017;77:12-22

[29] Grosse SD,Kenneson A,Wilfond BS.From public health emergency to public health service. the implications of evolving criteria for newborn screening panels.Pediatrics2006;117:923-9

[30] Gehtland LM.Early Check. A north carolina research partnership.NC Med J2019;80:59-61

[31] Rigaud C,Touraine R.Natural history of Barth syndrome: a national cohort study of 22 patients.Orphanet J Rare Dis2013;8:70 PMCID:PMC3656783

[32] Spencer CT,Day J.Cardiac and clinical phenotype in Barth syndrome.Pediatrics2006;118:E337-46

[33] Clarke SL,Gonzalez IL.Barth syndrome.Orphanet J Rare Dis2013;8:23 PMCID:PMC3583704

[34] Palsson OS,Törnblom H,Simren M.Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom.Gastroenterology2020;158:1262-1273

[35] Kelley R. Management of diarrheal illness in patients with Barth syndrome. Available from: https://www.barthsyndrome.org.uk/userfiles/Factsheets/ManagementofDiarrheainBTHSFactSheet.pdf [Last accessed on 13 Sep 2024]

[36] Filler K,Bennett J.Association of mitochondrial dysfunction and fatigue. a review of the literature.BBA clinical2014;1:12-23 PMCID:PMC4136529

[37] Olivar-Villanueva M,Phoon CK.Neurological & psychological aspects of Barth syndrome: clinical manifestations and potential pathogenic mechanisms.Mitochondrion2021;61:188-95

[38] Kim AY,Manuel R,Hornby B.Quality of life in Barth syndrome.Ther Adv Rare Dis2022;3:26330040221093743 PMCID:PMC10032447

[39] Reynolds S,Daw E.A qualitative investigation of fatigue & its daily impacts as perceived by individuals with Barth syndrome & their families.Am J Occup Ther2023;77(Supplement 2):7711510338p1

[40] Thompson R,Wang S.Current and future treatment approaches for Barth syndrome.J Inherit Metab Dis2021;45:1

[41] Suzuki-Hatano S,Rizzo SA.AAV-mediated TAZ gene replacement restores mitochondrial and cardioskeletal function in Barth syndrome.Human Gene Therapy2019;30:139-54 PMCID:PMC6383582

[42] Wang S,Xu Y.AAV gene therapy prevents and reverse heart failure in a murine knockout model of Barth syndrome.Circulation Research2020;126:1024-39 PMCID:PMC7233109